Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04658862 · ClinicalTrials.gov registry record · Phase 3
A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder
A Phase 3 study of Urinary Bladder Neoplasms, sponsored by Janssen Research & Development.
- Active
- Registry status
- Phase 3
- Development phase
- 518
- Enrollment target
- 20
- Study locations
NCT04658862 is a Phase 3 study of Urinary Bladder Neoplasms that is active but no longer recruiting, run by Janssen Research & Development. The registered enrollment target is 518 participants, above the 286-participant average among 19 other Urinary Bladder Neoplasms trials with a reported enrollment target (81% higher). The trial reports 20 study locations across 10 states.
The verdict
NCT04658862, a Phase 3 study of Urinary Bladder Neoplasms, is active but no longer recruiting, sponsored by Janssen Research & Development.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 518 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of study is to compare bladder intact-event free survival (BI-EFS) in participants receiving TAR-200 in combination with intravenous (IV) cetrelimab versus concurrent chemoradiotherapy.
Conditions Studied
Interventions
- DRUG Cisplatin
- DRUG Gemcitabine
- DRUG TAR-200
- BIOLOGICAL Cetrelimab
- RADIATION Conventional radiation therapy
Study Locations (20)
California
- Loma Linda Univ Faculty Medic - Loma Linda
- University of Southern California - Los Angeles
- Providence Saint John s Health Center - Santa Monica
- Stanford University Medical Center - Stanford
Florida
- Boca Raton Regional Hospital - Boca Raton
- Urological Research Network - Hialeah
- Memorial Healthcare System - Pembroke Pines
North Carolina
- Duke University Medical Center - Durham
- Vidant Urology - Greenville - Greenville
- Wake Forest University Baptist Medical Center (WFUBMC) - Comprehensive Cancer Center - Winston-Salem
Colorado
- The Urology Center of Colorado - Denver
- Foothills Urology - Golden Off - Golden
Michigan
- University Hospitals Seidman Cancer Center - Ann Arbor
- Michigan Institute of Urology - Troy
New Jersey
- Garden State Urology - Morristown
- New Jersey Urology LLC - Voorhees Township
Georgia
- Winship Cancer Institute of Emory University - Atlanta
Illinois
- DuPage Medical Group - Lisle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 518 participants |
| Start Date | 2020-12-07 |
| Est. Completion | 2028-12-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04658862
The ClinicalTrials.gov registry entry for NCT04658862 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 518 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 286-participant average among 19 other Urinary Bladder Neoplasms trials with a reported enrollment target (81% higher). The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Urinary Bladder Neoplasms appearing as the primary indexed condition, and to 5 interventions - of which Cisplatin is the first listed.
NCT04658862 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, Florida, North Carolina.
Frequently Asked Questions
What is clinical trial NCT04658862 about?
NCT04658862 is a clinical study titled "A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder". The purpose of study is to compare bladder intact-event free survival (BI-EFS) in participants receiving TAR-200 in combination with intravenous (IV) cetrelimab versus concurrent chemoradiotherapy.
What is the current status of trial NCT04658862?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 518 participants. The study started on 2020-12-07. Estimated completion is 2028-12-31.
What conditions does trial NCT04658862 study?
This clinical trial studies the following conditions: Urinary Bladder Neoplasms.
What interventions are being tested in trial NCT04658862?
The interventions under investigation include: Cisplatin (DRUG), Gemcitabine (DRUG), TAR-200 (DRUG), Cetrelimab (BIOLOGICAL), Conventional radiation therapy (RADIATION).
Who is sponsoring clinical trial NCT04658862?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04658862 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Urinary Bladder Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
RECRUITING · Phase 3
-
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer
ACTIVE NOT RECRUITING · Phase 3
-
Larotaxel + Cisplatin Versus Gemcitabine + Cisplatin in First Line Treatment of Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer
COMPLETED · Phase 3
-
FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3
RECRUITING · Phase 1
-
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.